Mianserin (Mianserin Hydrochloride)

Mianserin blocks central α2‑adrenergic receptors and antagonizes several serotonin receptors (5‑HT2, 5‑HT3) as well as histamine H1 receptors. This combined antagonism increases the availability of norepinephrine and serotonin in the brain, which contributes to its antidepressant and anxiolytic actions.

The appropriate dose of Mianserin is individualized by a qualified prescriber based on the patient’s clinical condition, response, and tolerability. Dosage regimens can vary, and the prescribing physician will determine the exact amount and schedule.

Safety data for Mianserin during pregnancy and lactation are limited, and the drug is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To order Mianserin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), Mianserin has a broader receptor profile, affecting both noradrenergic and serotonergic pathways as well as histamine receptors. This can result in a different side‑effect spectrum, such as more sedation and weight gain, but may be advantageous for patients who do not respond adequately to SSRIs.

Mianserin tablets should be stored at ambient temperature, preferably below 25 °C. Keep the medication in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Mianserin is taken orally as a tablet, usually with a glass of water. It can be taken with or without food, but consistency in relation to meals helps maintain stable absorption. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include agranulocytosis (a severe drop in white blood cells), seizures, marked hypotension, cardiac arrhythmias, hepatic dysfunction, and the emergence or worsening of suicidal thoughts. Any sudden or severe symptoms should prompt immediate medical evaluation.

Mianserin should be avoided in individuals with known hypersensitivity to the drug or its components, those currently taking monoamine oxidase inhibitors, and patients with uncontrolled cardiovascular disease that could be worsened by hypotension. Caution is also advised for patients with a history of blood dyscrasias or severe liver impairment.